>
Fa   |   Ar   |   En
   Incidence and characteristics of patients with visual impairment due to macular edema secondary to retinal vein occlusion in a representative Canadian cohort  
   
نویسنده petrella r.j. ,blouin j. ,davies b. ,barbeau m.
منبع journal of ophthalmology - 2012 - دوره : 2012 - شماره : 0
چکیده    Retinal vein occlusion (rvo) is an obstruction of the retinal venous system,and macular edema (me) is a complication of rvo that can lead to blindness. the canadian incidence of visual impairment (vi) due to me secondary to rvo is unknown. this observational,retrospective study used records from the southwestern ontario database to observe the annual incidence,demographics,and comorbidity characteristics of patients with vi due to me secondary to rvo. from 47,166 patients,73 with rvo (>40 years old) were identified: 53 with branch retinal vein occlusion (brvo),20 with central retinal vein occlusion (crvo). the annual incidence of vi (visual acuity <20/40 in snellen equivalent) due to me secondary to brvo was (mean (95%ci)) 0.056% (0.011-0.072),and to crvo was 0.021% (0.008-0.081). furthermore,a greater proportion of rvo patients had hypertension (68% versus 14%) or dyslipidemia (16% versus 10%),when compared to a healthy control cohort of 76,077 subjects (p<0.05). this study presents a description of the characteristics of patients with vi due to me secondary to rvo in a real-world canadian setting. the results demonstrate that brvo was more frequent than crvo,and that rvo in this patient population was associated with several vascular comorbidities. © 2012 robert j. petrella et al.
آدرس aging,rehabilitation and geriatric care program,lawson health research institute,london,on n6c 2r5,canada,individual health outcomes inc.,on,canada,parkwood hospital,aging,rehabilitation and geriatric care research center b-3002,801 commissioners rd e.,london, Canada, outcomes research,novartis pharmaceuticals canada inc.,dorval, Canada, outcomes research,novartis pharmaceuticals canada inc.,dorval, Canada, outcomes research,novartis pharmaceuticals canada inc.,dorval, Canada
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved